Classic photodynamic therapy (PDT) functions with an external light source. This external light source limits the use of classic PDT to treatment of superficial tumors (dermatology applications or during open surgery when removing the tumor).
The objective of our new approach is to extend the use of classic PDT to treatment of deeper tumors. The technology used, incidentally also allows a much better targeting of the tumors
The core innovative step is to go from a multimolecular approach as used in classic PDT to a monomolecular approach that we call PDT Cherenkov.
The molecule that we developed contains its own radiation source that leads the molecule to improve the production of oxygen free radicals (highly toxic for cells) more than classic PDT. This molecule can be linked to specific antibodies, for instance, to target it against tumor cells only.
Exogenous light source is not necessary anymore and Cherenkov PDT can be applied, through injection, on deep tissues (invasive tumor, metastasis) without surgery.
MARKETS & APPLICATIONS
Targeting the molecular structures with antibodies are ongoing
In vivo studies are to come
French patent application submitted on October 26th, 2018
+33 (0)6 17 06 68 07